Navigation Links
WuXi PharmaTech Announces Third Quarter 2008 Results
Date:11/12/2008

Third Quarter Net Revenues Up 98% and Adjusted EBITDA Up 70% Year-Over-Year

SHANGHAI, China, Nov. 12 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced its unaudited financial results for the third quarter ended September 30, 2008. During the quarter, WuXi's net revenue increased 98% year-over-year to $67.5 million, and diluted earnings per ADS were $0.10.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Commenting on the third quarter 2008 results, Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech, said, "WuXi continues to deliver strong revenue and profitability growth, as reflected in 98% year-over-year top-line revenue and 70% adjusted EBITDA growth. As we disclosed in the pre- announcement, the constricted biotech financing environment is impacting the CRO industry. However, we believe the need for outsourced development and manufacturing services will continue to be robust in the longer term. WuXi will continually work with WuXi's customers to bring their programs from bench to the market sooner and less costly.

"We are dedicated to maintaining and expanding WuXi's preferred provider status with our customers. In addition to delivering high-quality, IP- protected services efficiently, we will continue to position WuXi for the future to improve the success of discovery and shorten development time for our customers. This commitment requires us to expand WuXi's capacity and capabilities to meet our customers' expanding
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
2. WuXi PharmaTech Schedules Third Quarter 2008 Earnings Release on Wednesday, November 12, 2008
3. WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance
4. WuXi PharmaTech Appoints Jeff Leng to Its Board of Directors
5. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
6. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
7. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
8. Warburg Pincus Acquires 5.4% of WuXi PharmaTechs Outstanding Ordinary Shares from United Overseas Bank
9. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
10. WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy
11. WuXi PharmaTech (NYSE: WX) Named the Most Innovative Company in China and CEO Dr. Li the Most Innovative Leader of Chinese Enterprises
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 The report provides ... its definition, classification, application and industry overview. ... process, and product cost structure. Production is ... analysis also covers upstream raw materials, equipment, ... trend and proposals. In the end, the ...
(Date:12/24/2014)... Diego, CA (PRWEB) December 23, 2014 ... where their Twitter followers can submit their #HolidayInTheLab ... themselves and their lab mates. , For those struggling ... lab mates, the Pipette.com Holiday in the Lab Contest ... Pipette.com Twitter followers to send pictures of ...
(Date:12/24/2014)... December 23, 2014 PharmaBoardroom,s ... out today and available for free download , digs ... change and growth in the sector today. One ... successes has been in developing a homegrown pharmaceutical manufacturing base, ... production still remains some way off. A cursory comparison with ...
(Date:12/24/2014)... YORK , Dec. 23, 2014  NeuroLifeSciences announced ... mazindol in children with attention deficit/hyperactivity disorder published in ... . The paper, titled "Pilot Phase ... disorder" ( Konofal et al, Drug Des ... ) shows that mazindol might be an effective, ...
Breaking Biology Technology:Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3
... top question of Jatropha developers is, "What impact will ... and its prominence as a viable, sustainable biofuel?" To ... January webinar has been scheduled. As a precursor to ... crucial answers to hard-hitting inquiries by Jatropha investors. ...
... SEATTLE, Jan. 14 In meetings held in association,with ... Therapeutics,Inc. (CTI) (Nasdaq and MTA: CTIC) reviewed 2009 targeted ... new drug approvals in 2009 in,addition to potential label ... venture with Spectrum Pharmaceuticals, Inc.,(Spectrum) for Zevalin. , ...
... Photonics West 2009PITTSFIELD, Mass., and BELLINGHAM, Wash., Jan. ... and photonics, and Laurin Publishing, publisher of Photonics ... the 2008 Prism Awards for Photonics Innovation, the ... Prism Awards, introduced for the first time in ...
Cached Biology Technology:Jatropha Sector Reality Check: Still Viable In Volatile Times? Upcoming Webcast Shares Latest Insights 2Jatropha Sector Reality Check: Still Viable In Volatile Times? Upcoming Webcast Shares Latest Insights 3Jatropha Sector Reality Check: Still Viable In Volatile Times? Upcoming Webcast Shares Latest Insights 4Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 2Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 3Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 4Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 5Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 6SPIE and Laurin Publishing Announce Prism Awards Finalists 2SPIE and Laurin Publishing Announce Prism Awards Finalists 3
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, ... fine-scale differences in genetic ancestry of individuals from across ... Since immigrants first arrived more than four hundred years ... served as a meeting place for peoples from different ... ongoing mixing of peoples with African, European, and American ...
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, ... licensed its PerformTek biometric technology to industry leaders such ... highly accurate, clinically validated, biometric wearable products. These products ... 6-9 in Las Vegas . ... technology is accurate, flexible and robust – with the ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... molecular and protein signatures that predict rapid onset of ... transplant. The markers appeared soon after transplant and ... Such early detection of susceptibility to hepatitis C virus-induced ... treatment options after a transplant. Also, because the ...
... charcoal preserved in deeply buried sediments in Egypt,s Nile ... a huge drought 4,200 years ago associated with the ... the pyramid-building time. "Humans have a long history ... Bernhardt, a researcher with the U.S. Geological Survey. "Along ...
... NC Leukemia and lymphoma patients who receive life-saving ... side effects that significantly decrease quality of life, can ... In chronic Graft vs. Host Disease ... and the recipient,s body often cause these immune cells ...
Cached Biology News:Molecular and protein markers discovered for liver transplant failure from hepatitis C 2Molecular and protein markers discovered for liver transplant failure from hepatitis C 3Molecular and protein markers discovered for liver transplant failure from hepatitis C 4Climate and drought lessons from ancient Egypt 2B cell survival holds key to chronic graft vs. host disease 2
... uses the Adept CE 4100 high pressure dual ... detector for added flexibility and utra low drift. ... to a photodiode array detection and provides superior ... required for method development and for monitoring to ...
Rabbit anti Xanthine Oxidase Xanthine Oxidase, Bovine Buttermilk...
... number is a new ... easily match Cornings product ... availability yet, please order ... number (Z71,448-8) or contact ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (E6027) or contact customer s...
Biology Products: